Nathan B. Fountain - 04 Jun 2025 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Director
Signature: /s/ Derek Meisner, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 04 Jun 2025
Transactions value $: $0
Form type: 4
Date filed: 05 Jun 2025, 16:57
Previous filing: 10 Jun 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Fountain Nathan B	Director	C/O ACUMEN PHARMACEUTICALS, INC., 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON	/s/ Derek Meisner, Attorney-in-Fact	2025-06-05	0001869596

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Award	$0	+12.8K	+204.8%	$0.00	19.1K	04 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Stock Option (right to buy)	Award	$0	+19.5K		$0.00	19.5K	04 Jun 2025	Common Stock	19.5K	$1.07	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2	The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.